Paper Details 
Original Abstract of the Article :
OBJECTIVE: To investigate the prevalence and cause of early discontinuation (DC) of androgen receptor inhibitor (ARi) in advanced prostate cancer (PCa) patients. Additionally, to study the effect of changing ARi vs dose reduction on duration of treatment (DOT). MATERIALS AND METHODS: A retrospectiv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/j.urology.2022.12.025

データ提供:米国国立医学図書館(NLM)

Androgen Receptor Inhibitors for Advanced Prostate Cancer: Optimizing Treatment Duration

Advanced prostate cancer (PCa) presents a significant challenge for clinicians and patients alike. Imagine a desert oasis, teeming with life, but also harboring hidden dangers. Androgen receptor inhibitors (ARi) are like oases in the desert of PCa treatment, offering a haven for patients seeking to manage the disease. This study investigates the prevalence and causes of early discontinuation (DC) of ARi in advanced PCa patients, analyzing physician management strategies to maximize treatment duration. The authors found that DC rates were higher than reported in previous trials, with side effects, death, and cancer progression being the primary reasons. They also observed that changing ARi medication, but not dose reduction, was associated with a longer duration of treatment.

Maximizing Treatment Duration: A Strategic Approach

This study highlights the need for strategic approaches to optimize treatment duration for advanced PCa patients. The findings suggest that changing ARi medication may be a more effective strategy for prolonging treatment compared to dose reduction. This research provides valuable insights for clinicians seeking to personalize treatment plans and maximize patient benefits.

Navigating Advanced PCa: A Collaborative Journey

Advanced PCa requires a collaborative approach between clinicians, researchers, and patients. This study underscores the importance of understanding the factors that contribute to early DC, allowing for more effective management strategies. It also highlights the need for open communication between patients and clinicians to address concerns and optimize treatment outcomes.

Dr.Camel's Conclusion

The desert of advanced prostate cancer can be a daunting landscape, but this research offers valuable tools for navigating this challenging terrain. By understanding the factors that contribute to early discontinuation of ARi and employing strategic management approaches, clinicians can maximize treatment duration and improve outcomes for patients facing this formidable disease.

Date :
  1. Date Completed 2023-03-28
  2. Date Revised 2023-06-02
Further Info :

Pubmed ID

36603654

DOI: Digital Object Identifier

10.1016/j.urology.2022.12.025

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.